Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

By C. Leonardi, A. Kimball, K. Papp, N. Yeilding, C. Guzzo, Yuhua Wang, Shu Li, L. Dooley, K. Gordon. The Lancet, 2008

1,801 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab (2011, result): “The analyses did not detect a shift from a T H 1 to a T H 2 bias in the systemic immune system after ustekinumab treatment, which is further supported by the clinical data from the phase 3 clinical studies that showed no increase in asthma or allergic response”
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. (2009, background): “These observations led to the new definition of psoriasis as a T helper (Th) 1-type disease (Lew et al., 2004).”